Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Earns Hold (C) Rating from Weiss Ratings

Key Points

• Kiniksa Pharmaceuticals International (NASDAQ:KNSA) has been given a "hold (c)" rating by Weiss Ratings, with a consensus rating of "Moderate Buy" among analysts.
• The company's recent performance includes a reported quarterly earnings per share (EPS) of $0.23, exceeding analysts' expectations of $0.18.
• Insider selling has been notable, with significant shares sold by Director Thomas Malley and other executives, leading to a reported decrease in their ownership stakes.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report)'s stock had its "hold (c)" rating reiterated by investment analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

Other equities analysts have also issued reports about the stock. TD Cowen started coverage on shares of Kiniksa Pharmaceuticals International in a research report on Monday, September 29th. They set a "buy" rating and a $60.00 price target on the stock. Wedbush reaffirmed an "outperform" rating and set a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a research report on Friday, October 3rd. Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "hold" rating in a research report on Monday. Finally, Jefferies Financial Group raised their price target on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a research report on Tuesday, July 29th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $44.29.

Kiniksa Pharmaceuticals International Price Performance

Shares of KNSA opened at $38.31 on Wednesday. The firm has a market capitalization of $2.84 billion, a PE ratio of 957.99 and a beta of 0.16. The company's 50-day moving average is $35.03 and its 200-day moving average is $28.97. Kiniksa Pharmaceuticals International has a fifty-two week low of $17.82 and a fifty-two week high of $39.12.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, topping analysts' consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The business had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. Analysts predict that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current fiscal year.

Insider Activity

In other Kiniksa Pharmaceuticals International news, Director Thomas Malley sold 78,233 shares of the stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $33.09, for a total transaction of $2,588,729.97. Following the sale, the director directly owned 12,546 shares in the company, valued at $415,147.14. This represents a 86.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Ross Moat sold 3,523 shares of the stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $35.31, for a total transaction of $124,397.13. Following the sale, the insider owned 9,415 shares in the company, valued at $332,443.65. The trade was a 27.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 603,371 shares of company stock valued at $20,434,869. Corporate insiders own 53.48% of the company's stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Hedge funds have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC boosted its stake in shares of Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company's stock valued at $25,000 after purchasing an additional 532 shares in the last quarter. Osaic Holdings Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals International in the 2nd quarter valued at approximately $31,000. GAMMA Investing LLC boosted its stake in shares of Kiniksa Pharmaceuticals International by 84.8% in the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after purchasing an additional 568 shares in the last quarter. US Bancorp DE acquired a new stake in shares of Kiniksa Pharmaceuticals International in the 1st quarter valued at approximately $33,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Kiniksa Pharmaceuticals International in the 2nd quarter valued at approximately $43,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.